Please wait while the formulary information is being retrieved.
Drug overview for DANAZOL (danazol):
Generic name: DANAZOL (DAY-nuh-zole)
Drug class: Androgens/Anabolic Steroids
Therapeutic class: Endocrine
Danazol is a synthetic derivative of ethisterone (ethinyl testosterone) with weak androgenic and anabolic properties and no estrogenic or progestogenic activity.
No enhanced Uses information available for this drug.
Generic name: DANAZOL (DAY-nuh-zole)
Drug class: Androgens/Anabolic Steroids
Therapeutic class: Endocrine
Danazol is a synthetic derivative of ethisterone (ethinyl testosterone) with weak androgenic and anabolic properties and no estrogenic or progestogenic activity.
No enhanced Uses information available for this drug.
DRUG IMAGES
DANAZOL 200 MG CAPSULE
DANAZOL 50 MG CAPSULE
DANAZOL 100 MG CAPSULE
The following indications for DANAZOL (danazol) have been approved by the FDA:
Indications:
Endometriosis
Fibrocystic breast disease
Prevention of angioedema attacks in patient with hereditary angioedema
Professional Synonyms:
Adenomyosis externa
Chronic cystic mastitis
Endometriosis externa
Prevention of angioedema attack in hereditary angioneurotic edema
Prevention of angioedema attacks in patient with HAE
Prophylaxis against angioedema attacks in patient with HAE
Indications:
Endometriosis
Fibrocystic breast disease
Prevention of angioedema attacks in patient with hereditary angioedema
Professional Synonyms:
Adenomyosis externa
Chronic cystic mastitis
Endometriosis externa
Prevention of angioedema attack in hereditary angioneurotic edema
Prevention of angioedema attacks in patient with HAE
Prophylaxis against angioedema attacks in patient with HAE
The following dosing information is available for DANAZOL (danazol):
Danazol is administered orally. For the treatment of endometriosis and fibrocystic breast disease, administration of the drug should be initiated during menstruation; otherwise, appropriate laboratory tests should be performed to ensure that the patient is not pregnant. Attempts should be made to determine the lowest possible effective dosage of the drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DANAZOL 50 MG CAPSULE | Maintenance | Adults take 1 capsule (50 mg) by oral route 2 times per day |
| DANAZOL 100 MG CAPSULE | Maintenance | Adults take 1 capsule (100 mg) by oral route 2 times per day |
| DANAZOL 200 MG CAPSULE | Maintenance | Adults take 1 capsule (200 mg) by oral route 2 times per day |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DANAZOL 100 MG CAPSULE | Maintenance | Adults take 1 capsule (100 mg) by oral route 2 times per day |
| DANAZOL 200 MG CAPSULE | Maintenance | Adults take 1 capsule (200 mg) by oral route 2 times per day |
| DANAZOL 50 MG CAPSULE | Maintenance | Adults take 1 capsule (50 mg) by oral route 2 times per day |
The following drug interaction information is available for DANAZOL (danazol):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Lovastatin (Greater Than 20 mg); Simvastatin/Danazol SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Danazol may inhibit the metabolism of lovastatin(1) and simvastatin(2) by CYP3A4. CLINICAL EFFECTS: Concurrent use of danazol may result in elevated levels of lovastatin(1) and simvastatin(2,3) and toxicity, including rhabdomyolysis. One case report of pancreatitis was possibly caused by the danazol/lovastatin interaction.(7) PREDISPOSING FACTORS: Higher doses of lovastatin(1) or simvastatin(2,3) may increase the risk of myopathy. The risk for myopathy or rhabdomyolysis may also be greater in patients 65 years and older, inadequately treated hypothyroidism, renal impairment, carnitine deficiency, malignant hyperthermia, or in patients with a history of myopathy or rhabdomyolysis. Patients with a SLCO1B1 polymorphism that leads to decreased function of the hepatic uptake transporter OATP1B1 may have increased statin concentrations and be predisposed to myopathy or rhabdomyolysis. PATIENT MANAGEMENT: The US manufacturer of lovastatin states that in patients receiving danazol, lovastatin should be started at a dose of 10 mg daily and that the dose of lovastatin should not exceed 20 mg daily. The benefits of concurrent use should be carefully weighed against the risk of the combination.(1) Do not use simvastatin with danazol.(2-4) DISCUSSION: Concurrent use of danazol with lovastatin(1) or simvastatin(2-4) increases the risk of rhabdomyolysis. Rhabdomyolysis(5-7) and pancreatitis(5) have been reported with concurrent lovastatin and danazol and with concurrent simvastatin and danazol.(8,9) One case involved death.(8) |
ALTOPREV, EZETIMIBE-SIMVASTATIN, FLOLIPID, LOVASTATIN, SIMVASTATIN, VYTORIN, ZOCOR |
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Selected Anticoagulants (Vit K antagonists)/Selected Anabolic Steroids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The exact mechanism is unknown. It has been hypothesized that the C-17 alkylated androgens may increase turnover of clotting factors and decrease their synthesis. Increased affinity for the anticoagulant receptor site has also been hypothesized. The C-17 alkylated androgens have not been shown to alter the metabolism of anticoagulants. CLINICAL EFFECTS: The concurrent use of anticoagulants and anabolic steroids may result in an increased risk for bleeding. PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: Patients should be closely monitored for increased anticoagulant activity. The dose of the anticoagulant may need to be adjusted. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. When concurrent therapy is warranted, also monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. DISCUSSION: Danazol, methandrostenolone, methyltestosterone, oxymetholone, and stanozolol have been shown to increase the hypoprothrombinemic actions of warfarin. Methyltestosterone has also been shown to increase the effects of dicumarol. Oxymetholone and ethylestrenol have been shown to increase the effects of phenindione. Limited data suggest that the non-C-17-alkylated androgens do not affect anticoagulants. |
ANISINDIONE, DICUMAROL, JANTOVEN, PHENINDIONE, WARFARIN SODIUM |
| Cyclosporine/Selected Androgens SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Danazol and methyltestosterone may inhibit the metabolism of cyclosporine. CLINICAL EFFECTS: Concurrent therapy may result in increased levels of cyclosporine, which may produce hepatic and renal dysfunction. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If possible, avoid giving patients receiving cyclosporine danazol or methyltestosterone. If concurrent therapy is warranted, monitor cyclosporine levels as well as renal and hepatic function carefully. Cyclosporine dosage adjustments may be necessary when these agents are initiated or discontinued, as well as during concurrent therapy. Discontinuation of the androgen may be necessary. DISCUSSION: Four case reports have documented increased cyclosporine levels during concurrent therapy with danazol.(1-4) In two of these reports, elevated cyclosporine levels persisted even after decreases in cyclosporine dosages.(1,2) One patient also experienced decreased renal function, as indicated by an increase in serum creatinine levels.(1) Cyclosporine levels returned to baseline following the discontinuation of danazol.(1-4) Two case reports have documented increased cyclosporine levels during concurrent therapy with methyltestosterone. Both patients experienced elevated cyclosporine, bilirubin, and serum creatinine levels during concurrent therapy.(5,6) In one patient, elevated cyclosporine levels persisted despite a 40% decrease in cyclosporine dosage.(5) Discontinuation of methyltestosterone resulted in a gradual return of cyclosporine levels to previous values.(5,6) |
CYCLOSPORINE, CYCLOSPORINE MODIFIED, GENGRAF, NEORAL, SANDIMMUNE |
There are 3 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Carbamazepine/Danazol SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Danazol-induced inhibition of CYP3A4, resulting in a decrease in carbamazepine metabolism. CLINICAL EFFECTS: May see an increase in the pharmacologic activity of carbamazepine, including carbamazepine toxicity. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: It may be necessary to reduce the dose of carbamazepine during concurrent administration of danazol. Monitor serum carbamazepine levels and monitor the patient for symptoms of carbamazepine toxicity. Adjust the dose accordingly. DISCUSSION: In six patients with epilepsy and fibrocystic breast disease the concentration in serum of antiepileptic drugs was obtained before, during, and after danazol therapy. (1) Carbamazepine serum level increased almost twofold in the presence of danazol. Danazol led to a pronounced inhibition of CBZ metabolism in an epileptic patient. (2) During danazol coadministration, CBZ elimination half-life increased from a pretreatment value of 11 to 24.3 h. Carbamazepine plasma clearance decreased from 57.7 to 23.2 ml/h/kg. Observations in five other female patients confirm that the steady-state plasma concentrations of CBZ increase between 50 and 100% during coadministration of danazol. |
CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, EPITOL, EQUETRO, TEGRETOL, TEGRETOL XR |
| Tacrolimus/Danazol SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Danazol may inhibit the metabolism of tacrolimus by CYP3A4.(1-3) CLINICAL EFFECTS: Concurrent use of danazol may result in elevated levels of and toxicity from tacrolimus, including nephrotoxicity, neurotoxicity, and prolongation of the QTc interval and life-threatening cardiac arrhythmias, including torsades de pointes.(1-3) PREDISPOSING FACTORS: The risk of QT prolongation or torsade de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsade de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age. Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsade de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibits its metabolism or elimination, and/or renal/hepatic dysfunction). PATIENT MANAGEMENT: Monitor tacrolimus levels in patients receiving concurrent danazol. The dosage of tacrolimus may need to be adjusted if danazol is initiated or discontinued.(1) When concurrent therapy of danazol and tacrolimus is warranted, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting. DISCUSSION: Concurrent danazol has been shown to increase tacrolimus trough concentrations (Cmin) by more than 5-fold in patients and by 3-fold in rats.(1) |
ASTAGRAF XL, ENVARSUS XR, PROGRAF, TACROLIMUS, TACROLIMUS XL |
| Lovastatin (Less than or Equal To 20 mg)/Danazol SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Danazol may inhibit the metabolism of lovastatin by CYP3A4.(1) CLINICAL EFFECTS: Concurrent use of danazol may result in elevated levels of lovastatin and toxicity, including rhabdomyolysis.(1) One case report also states pancreatitis may possibly be caused by the lovastatin danazol interaction.(4) PREDISPOSING FACTORS: The risk for myopathy or rhabdomyolysis may be greater in patients 65 years and older, inadequately treated hypothyroidism, renal impairment, carnitine deficiency, malignant hyperthermia, or in patients with a history of myopathy or rhabdomyolysis. Patients with a SLCO1B1 polymorphism that leads to decreased function of the hepatic uptake transporter OATP1B1 may have increased statin concentrations and be predisposed to myopathy or rhabdomyolysis. PATIENT MANAGEMENT: The US manufacturer of lovastatin states that in patients receiving danazol, lovastatin should be started at a dose of 10 mg daily and that the dose of lovastatin should not exceed 20 mg daily. The benefits of concurrent use should be carefully weighed against the risk of the combination.(1) DISCUSSION: Concurrent use of danazol with lovastatin increases the risk of rhabdomyolysis.(1) Rhabdomyolysis(2-4) and pancreatitis(2) have been reported with concurrent lovastatin and danazol. |
ALTOPREV, LOVASTATIN |
The following contraindication information is available for DANAZOL (danazol):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 6 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic heart failure |
| History of venous thromboembolism |
| Lactation |
| Porphyria |
| Pregnancy |
| Thromboembolic disorder |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Disease of liver |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Migraine |
| Seizure disorder |
The following adverse reaction information is available for DANAZOL (danazol):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 29 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abnormal vaginal bleeding Amenorrhea Breast size decreased Irregular menstrual periods |
Edema Virilism |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute arterial thromboembolism Acute intermittent porphyria Acute pancreatitis Carpal tunnel syndrome Cataracts Cerebrovascular accident Eosinophilia Gingival bleeding Hematuria Idiopathic intracranial hypertension Jaundice Leukocytosis Neoplasm of liver Nipple discharge Peliosis hepatis Rhabdomyolysis Skin rash Splenic peliosis Stevens-johnson syndrome Thrombocytopenic disorder Thromboembolic disorder Urticaria |
There are 14 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acne vulgaris Weight gain |
Alopecia Flushing Hypoestrogenism Vaginal dryness Voice change |
| Rare/Very Rare |
|---|
|
Hyperhidrosis Hyperlipidemia Mood changes Nervousness Oligospermia Pruritus of skin Skin photosensitivity |
The following precautions are available for DANAZOL (danazol):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Although there are no adequate and controlled studies to date in humans, danazol may cause fetal harm when administered to pregnant women. Androgenic effects including clitoral hypertrophy, labial fusion of the external genital fold to form a scrotal-like structure, ambiguous genitalia, abnormal vaginal development, and persistence of a urogenital sinus have occurred in the female offspring of women who were given danazol during pregnancy. Spontaneous abortions have also occurred in pregnant women who received the drug.
Since the risks clearly outweigh the possible benefits in women who are or may become pregnant, danazol is contraindicated in such women. Women of childbearing age should be instructed to use an effective, nonhormonal method of contraception during danazol therapy and be informed of the potential hazard to the fetus should they become pregnant during therapy. In addition, a reliable pregnancy test (e.g., beta-subunit radioimmunoassay (RIA)) must be performed immediately prior to beginning danazol therapy. If the drug is inadvertently administered during pregnancy or if the patient becomes pregnant while receiving the drug, administration of danazol should be discontinued, and the woman should be apprised of the potential risk to the fetus.
Since the risks clearly outweigh the possible benefits in women who are or may become pregnant, danazol is contraindicated in such women. Women of childbearing age should be instructed to use an effective, nonhormonal method of contraception during danazol therapy and be informed of the potential hazard to the fetus should they become pregnant during therapy. In addition, a reliable pregnancy test (e.g., beta-subunit radioimmunoassay (RIA)) must be performed immediately prior to beginning danazol therapy. If the drug is inadvertently administered during pregnancy or if the patient becomes pregnant while receiving the drug, administration of danazol should be discontinued, and the woman should be apprised of the potential risk to the fetus.
Because of the potential for serious adverse reactions to danazol in nursing infants, a decision should be made whether to discontinue nursing or not use the drug, taking into account the importance of the drug to the woman.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DANAZOL (danazol):
WARNING: This medication must not be used during pregnancy. It may harm an unborn baby. In women of childbearing age, this medication should be started during their menstrual period.
If not, then they should have a negative pregnancy test before starting this medication. It is important to prevent pregnancy while using this medication. Consult your doctor for more details and to discuss the use reliable forms of non-hormonal birth control (such as condoms, diaphragm with spermicide) while using this medication.
If you become pregnant or think you may be pregnant, tell your doctor right away. Danazol has rarely caused very serious (possibly fatal) blood clots (such as stroke), liver disease, and increased pressure on the brain (benign intracranial hypertension). Get medical help right away if you have any symptoms of these side effects, including nausea/vomiting that doesn't stop, headache that is severe or doesn't go away, weakness on one side of the body, trouble speaking, vision changes, severe stomach/abdominal pain, dark urine, yellowing eyes/skin, mental/mood changes (such as confusion).
WARNING: This medication must not be used during pregnancy. It may harm an unborn baby. In women of childbearing age, this medication should be started during their menstrual period.
If not, then they should have a negative pregnancy test before starting this medication. It is important to prevent pregnancy while using this medication. Consult your doctor for more details and to discuss the use reliable forms of non-hormonal birth control (such as condoms, diaphragm with spermicide) while using this medication.
If you become pregnant or think you may be pregnant, tell your doctor right away. Danazol has rarely caused very serious (possibly fatal) blood clots (such as stroke), liver disease, and increased pressure on the brain (benign intracranial hypertension). Get medical help right away if you have any symptoms of these side effects, including nausea/vomiting that doesn't stop, headache that is severe or doesn't go away, weakness on one side of the body, trouble speaking, vision changes, severe stomach/abdominal pain, dark urine, yellowing eyes/skin, mental/mood changes (such as confusion).
The following icd codes are available for DANAZOL (danazol)'s list of indications:
| Endometriosis | |
| N80 | Endometriosis |
| N80.0 | Endometriosis of uterus |
| N80.00 | Endometriosis of the uterus, unspecified |
| N80.01 | Superficial endometriosis of the uterus |
| N80.02 | Deep endometriosis of the uterus |
| N80.1 | Endometriosis of ovary |
| N80.10 | Endometriosis of ovary, unspecified depth |
| N80.101 | Endometriosis of right ovary, unspecified depth |
| N80.102 | Endometriosis of left ovary, unspecified depth |
| N80.103 | Endometriosis of bilateral ovaries, unspecified depth |
| N80.109 | Endometriosis of ovary, unspecified side, unspecified depth |
| N80.11 | Superficial endometriosis of the ovary |
| N80.111 | Superficial endometriosis of right ovary |
| N80.112 | Superficial endometriosis of left ovary |
| N80.113 | Superficial endometriosis of bilateral ovaries |
| N80.119 | Superficial endometriosis of ovary, unspecified ovary |
| N80.12 | Deep endometriosis of ovary |
| N80.121 | Deep endometriosis of right ovary |
| N80.122 | Deep endometriosis of left ovary |
| N80.123 | Deep endometriosis of bilateral ovaries |
| N80.129 | Deep endometriosis of ovary, unspecified ovary |
| N80.2 | Endometriosis of fallopian tube |
| N80.20 | Endometriosis of fallopian tube, unspecified depth |
| N80.201 | Endometriosis of right fallopian tube, unspecified depth |
| N80.202 | Endometriosis of left fallopian tube, unspecified depth |
| N80.203 | Endometriosis of bilateral fallopian tubes, unspecified depth |
| N80.209 | Endometriosis of unspecified fallopian tube, unspecified depth |
| N80.21 | Superficial endometriosis of fallopian tube |
| N80.211 | Superficial endometriosis of right fallopian tube |
| N80.212 | Superficial endometriosis of left fallopian tube |
| N80.213 | Superficial endometriosis of bilateral fallopian tubes |
| N80.219 | Superficial endometriosis of unspecified fallopian tube |
| N80.22 | Deep endometriosis of the fallopian tube |
| N80.221 | Deep endometriosis of right fallopian tube |
| N80.222 | Deep endometriosis of left fallopian tube |
| N80.223 | Deep endometriosis of bilateral fallopian tubes |
| N80.229 | Deep endometriosis of unspecified fallopian tube |
| N80.3 | Endometriosis of pelvic peritoneum |
| N80.30 | Endometriosis of pelvic peritoneum, unspecified |
| N80.31 | Endometriosis of the anterior cul-de-sac |
| N80.311 | Superficial endometriosis of the anterior cul-de-sac |
| N80.312 | Deep endometriosis of the anterior cul-de-sac |
| N80.319 | Endometriosis of the anterior cul-de-sac, unspecified depth |
| N80.32 | Endometriosis of the posterior cul-de-sac |
| N80.321 | Superficial endometriosis of the posterior cul-de-sac |
| N80.322 | Deep endometriosis of the posterior cul-de-sac |
| N80.329 | Endometriosis of the posterior cul-de-sac, unspecified depth |
| N80.33 | Superficial endometriosis of the pelvic sidewall |
| N80.331 | Superficial endometriosis of the right pelvic sidewall |
| N80.332 | Superficial endometriosis of the left pelvic sidewall |
| N80.333 | Superficial endometriosis of bilateral pelvic sidewall |
| N80.339 | Superficial endometriosis of pelvic sidewall, unspecified side |
| N80.34 | Deep endometriosis of the pelvic sidewall |
| N80.341 | Deep endometriosis of the right pelvic sidewall |
| N80.342 | Deep endometriosis of the left pelvic sidewall |
| N80.343 | Deep endometriosis of the bilateral pelvic sidewall |
| N80.349 | Deep endometriosis of the pelvic sidewall, unspecified side |
| N80.35 | Endometriosis of the pelvic sidewall, unspecified depth |
| N80.351 | Endometriosis of the right pelvic sidewall, unspecified depth |
| N80.352 | Endometriosis of the left pelvic sidewall, unspecified depth |
| N80.353 | Endometriosis of bilateral pelvic sidewall, unspecified depth |
| N80.359 | Endometriosis of pelvic sidewall, unspecified side, unspecified depth |
| N80.36 | Superficial endometriosis of the pelvic brim |
| N80.361 | Superficial endometriosis of the right pelvic brim |
| N80.362 | Superficial endometriosis of the left pelvic brim |
| N80.363 | Superficial endometriosis of bilateral pelvic brim |
| N80.369 | Superficial endometriosis of the pelvic brim, unspecified side |
| N80.37 | Deep endometriosis of the pelvic brim |
| N80.371 | Deep endometriosis of the right pelvic brim |
| N80.372 | Deep endometriosis of the left pelvic brim |
| N80.373 | Deep endometriosis of bilateral pelvic brim |
| N80.379 | Deep endometriosis of the pelvic brim, unspecified side |
| N80.38 | Endometriosis of the pelvic brim, unspecified depth |
| N80.381 | Endometriosis of the right pelvic brim, unspecified depth |
| N80.382 | Endometriosis of the left pelvic brim, unspecified depth |
| N80.383 | Endometriosis of bilateral pelvic brim, unspecified depth |
| N80.389 | Endometriosis of the pelvic brim, unspecified side, unspecified depth |
| N80.39 | Endometriosis of other pelvic peritoneum |
| N80.391 | Superficial endometriosis of the pelvic peritoneum, other specified sites |
| N80.392 | Deep endometriosis of the pelvic peritoneum, other specified sites |
| N80.399 | Endometriosis of the pelvic peritoneum, other specified sites, unspecified depth |
| N80.3A | Superficial endometriosis of the uterosacral ligament(s) |
| N80.3A1 | Superficial endometriosis of the right uterosacral ligament |
| N80.3A2 | Superficial endometriosis of the left uterosacral ligament |
| N80.3A3 | Superficial endometriosis of the bilateral uterosacral ligament(s) |
| N80.3A9 | Superficial endometriosis of the uterosacral ligament(s), unspecified side |
| N80.3B | Deep endometriosis of the uterosacral ligament(s) |
| N80.3B1 | Deep endometriosis of the right uterosacral ligament |
| N80.3B2 | Deep endometriosis of the left uterosacral ligament |
| N80.3B3 | Deep endometriosis of bilateral uterosacral ligament(s) |
| N80.3B9 | Deep endometriosis of the uterosacral ligament(s), unspecified side |
| N80.3C | Endometriosis of the uterosacral ligament(s), unspecified depth |
| N80.3C1 | Endometriosis of the right uterosacral ligament, unspecified depth |
| N80.3C2 | Endometriosis of the left uterosacral ligament, unspecified depth |
| N80.3C3 | Endometriosis of bilateral uterosacral ligament(s), unspecified depth |
| N80.3C9 | Endometriosis of the uterosacral ligament(s), unspecified side, unspecified depth |
| N80.4 | Endometriosis of rectovaginal septum and vagina |
| N80.40 | Endometriosis of rectovaginal septum, unspecified involvement of vagina |
| N80.41 | Endometriosis of rectovaginal septum without involvement of vagina |
| N80.42 | Endometriosis of rectovaginal septum with involvement of vagina |
| N80.5 | Endometriosis of intestine |
| N80.50 | Endometriosis of intestine, unspecified |
| N80.51 | Endometriosis of the rectum |
| N80.511 | Superficial endometriosis of the rectum |
| N80.512 | Deep endometriosis of the rectum |
| N80.519 | Endometriosis of the rectum, unspecified depth |
| N80.52 | Endometriosis of the sigmoid colon |
| N80.521 | Superficial endometriosis of the sigmoid colon |
| N80.522 | Deep endometriosis of the sigmoid colon |
| N80.529 | Endometriosis of the sigmoid colon, unspecified depth |
| N80.53 | Endometriosis of the cecum |
| N80.531 | Superficial endometriosis of the cecum |
| N80.532 | Deep endometriosis of the cecum |
| N80.539 | Endometriosis of the cecum, unspecified depth |
| N80.54 | Endometriosis of the appendix |
| N80.541 | Superficial endometriosis of the appendix |
| N80.542 | Deep endometriosis of the appendix |
| N80.549 | Endometriosis of the appendix, unspecified depth |
| N80.55 | Endometriosis of other parts of the colon |
| N80.551 | Superficial endometriosis of other parts of the colon |
| N80.552 | Deep endometriosis of other parts of the colon |
| N80.559 | Endometriosis of other parts of the colon, unspecified depth |
| N80.56 | Endometriosis of the small intestine |
| N80.561 | Superficial endometriosis of the small intestine |
| N80.562 | Deep endometriosis of the small intestine |
| N80.569 | Endometriosis of the small intestine, unspecified depth |
| N80.6 | Endometriosis in cutaneous scar |
| N80.8 | Other endometriosis |
| N80.9 | Endometriosis, unspecified |
| N80.A | Endometriosis of bladder and ureters |
| N80.A0 | Endometriosis of bladder, unspecified depth |
| N80.A1 | Superficial endometriosis of bladder |
| N80.A2 | Deep endometriosis of bladder |
| N80.A4 | Superficial endometriosis of ureter |
| N80.A41 | Superficial endometriosis of right ureter |
| N80.A42 | Superficial endometriosis of left ureter |
| N80.A43 | Superficial endometriosis of bilateral ureters |
| N80.A49 | Superficial endometriosis of unspecified ureter |
| N80.A5 | Deep endometriosis of ureter |
| N80.A51 | Deep endometriosis of right ureter |
| N80.A52 | Deep endometriosis of left ureter |
| N80.A53 | Deep endometriosis of bilateral ureters |
| N80.A59 | Deep endometriosis of unspecified ureter |
| N80.A6 | Endometriosis of ureter, unspecified depth |
| N80.A61 | Endometriosis of right ureter, unspecified depth |
| N80.A62 | Endometriosis of left ureter, unspecified depth |
| N80.A63 | Endometriosis of bilateral ureters, unspecified depth |
| N80.A69 | Endometriosis of unspecified ureter, unspecified depth |
| N80.B | Endometriosis of cardiothoracic space |
| N80.B1 | Endometriosis of pleura |
| N80.B2 | Endometriosis of lung |
| N80.B3 | Endometriosis of diaphragm |
| N80.B31 | Superficial endometriosis of diaphragm |
| N80.B32 | Deep endometriosis of diaphragm |
| N80.B39 | Endometriosis of diaphragm, unspecified depth |
| N80.B4 | Endometriosis of the pericardial space |
| N80.B5 | Endometriosis of the mediastinal space |
| N80.B6 | Endometriosis of cardiothoracic space |
| N80.C | Endometriosis of the abdomen |
| N80.C0 | Endometriosis of the abdomen, unspecified |
| N80.C1 | Endometriosis of the anterior abdominal wall |
| N80.C10 | Endometriosis of the anterior abdominal wall, subcutaneous tissue |
| N80.C11 | Endometriosis of the anterior abdominal wall, fascia and muscular layers |
| N80.C19 | Endometriosis of the anterior abdominal wall, unspecified depth |
| N80.C2 | Endometriosis of the umbilicus |
| N80.C3 | Endometriosis of the inguinal canal |
| N80.C4 | Endometriosis of extra-pelvic abdominal peritoneum |
| N80.C9 | Endometriosis of other site of abdomen |
| N80.D | Endometriosis of the pelvic nerves |
| N80.D0 | Endometriosis of the pelvic nerves, unspecified |
| N80.D1 | Endometriosis of the sacral splanchnic nerves |
| N80.D2 | Endometriosis of the sacral nerve roots |
| N80.D3 | Endometriosis of the obturator nerve |
| N80.D4 | Endometriosis of the sciatic nerve |
| N80.D5 | Endometriosis of the pudendal nerve |
| N80.D6 | Endometriosis of the femoral nerve |
| N80.D9 | Endometriosis of other pelvic nerve |
| Fibrocystic breast disease | |
| N60.1 | Diffuse cystic mastopathy |
| N60.11 | Diffuse cystic mastopathy of right breast |
| N60.12 | Diffuse cystic mastopathy of left breast |
| N60.19 | Diffuse cystic mastopathy of unspecified breast |
| N60.3 | Fibrosclerosis of breast |
| N60.31 | Fibrosclerosis of right breast |
| N60.32 | Fibrosclerosis of left breast |
| N60.39 | Fibrosclerosis of unspecified breast |
| Prevention of angioedema attack in hereditary angioedema | |
| D84.1 | Defects in the complement system |
Formulary Reference Tool